Please login to the form below

Not currently logged in
Email:
Password:

US prescribing info update for Onglyza

The FDA has approved an update to prescribing information for Onglyza, a type 2 diabetes therapy from AstraZeneca and Bristol-Myers Squibb

The US Food and Drug Administration (FDA) has approved an update to prescribing information for Onglyza (saxagliptin), a type 2 diabetes therapy from AstraZeneca (AZ) and Bristol-Myers Squibb (BMS).

The prescribing information will be updated to reflect data from two clinical studies, the first of which investigated the safety and efficacy of Onglyza in patients with moderate to severe renal impairment or end-stage renal disease (ESRD). Data at 12 weeks showed that Onglyza 2.5mg once-daily significantly improved glycosylated haemoglobin (HbA1c) from baseline compared to placebo when added to patients' current diabetes treatment.

The second study, which took place over 52 weeks, compared Onglyza to titrated glipizide in patients with inadequate glyceamic control on metformin therapy plus diet and exercise. Data showed that Onglyza plus metformin provided similar HbA1c reductions from baseline. Onglyza plus metformin also resulted in significantly less confirmed hypoglycaemia, as well as weight loss compared to weight gain versus titrated glipizide plus metformin.  

Onglyza was approved by the FDA in July 2009 as an adjunct to diet and exercise to improve glyceamic (blood sugar) control in adults with type 2 diabetes mellitus in multiple clinical settings. 

Onglyza is approved in 56 countries, including the US, Canada, Mexico, Chile, India, Brazil, Argentina and 30 European nations and has been submitted for regulatory review in more than 87 countries.

Bristol-Myers Squibb and AstraZeneca produce Onglyza in partnership as part of a collaboration set up between the two companies in January 2007 to research, develop and commercialise select investigational drugs for type 2 diabetes.

23rd February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

A snapshot of… Exscientia
...
Patients are ready for virtual clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...

Infographics